Currently FDA/PI staining is the standard assessment of human pancreatic islet viability with suitability for transplantation when viability score is above 70%.
FDA/PI staining remains the standard assessment tool for determining the viability and transplant potential of human pancreatic islets, with a threshold of above 70% viability.